Skip to main content

Table 2 Subject-reported clinical variables among three subgroups (N = 229)

From: Cross-cultural adaptation and validation of the Finnish version of the central sensitization inventory and its relationship with dizziness and postural control

 

Pain free control group (N = 42)

Chronic pain in a single body area (N = 79)

Multisite pain (two or more chronic pain locations) (N = 108)

p-value

Comparison between three groups

Yes

No

Yes

No

Yes

No

χ2

χ2

Chronic low back pain

0 (0%)

42 (100%)

56 (71%)

23 (29%)

105 (97%)

3 (3%)

< 0.001*

a (< 0.001*)

b (< 0.001*)

c (< 0.001*)

Referral to leg or leg pain (if chronic low back pain was indicated)

0 (0%)

42 (100%)

28 (35%)

51 (65%)

59 (55%)

49 (45%)

< 0.001*

a (< 0.001*)

b (< 0.001*)

Other chronic musculoskeletal pain

0 (0%)

42 (100%)

23 (29%)

56 (71%)

106

(98%)

2 (2%)

< 0.001*

a (< 0.001*)

b (< 0.001*)

c (< 0.001*)

Subject reported Chronic headache

0 (0%)

42 (100%)

0 (0%)

71 (100%)

24 (22%)

84 (78%)

< 0.001*

b (< 0.001*)

c (< 0.001*)

Previous Rheumatic disease diagnosis

0 (0%)

42 (100%)

2 (2%)

77 (98%)

8 (7%)

100 (93%)

0.84

 

Dizziness during last 12 months

4 (10%)

38 (90%)

9 (11%)

70 (89%)

40 (37%)

68 (63%)

< 0.001*

b (< 0.001*)

c (< 0.001*)

    

One-Way ANOVA

Post hoc LSD

Numerical pain scale

0 ± 0

3.8 ± 2.8

4.7 ± 2.1

< 0.001*

a (< 0.001*)

b (< 0.001*)

Pain in months

0 ± 0

39.7 ± 6.9

76.7 ± 83.7

< 0.001*

a (0.04*)

b (< 0.001*)

c (< 0.001*)

CSI score

28.0 ± 10.7

31.8 ± 10.1

40.7 ± 11.7

< 0.001*

b (< 0.001*)

c (< 0.001*)

TSK

25.8 ± 4.9

30.2 ± 6.8

33.0 ± 7.7

< 0.001*

a (0.01*)

b (< 0.001*)

DEPS

5.4 ± 4.3

4.8 ± 3.9

7.3 ± 5.4

0.01*

c (< 0.001*)

RMDQ

0.4 ± 0.9

2.6 ± 3.1

4.4 ± 3.7

< 0.001*

a (< 0.001*)

b (< 0.001*)

c (< 0.001*)

PSQ-3

2.0 ± 3.6

6.2 ± 6.6

9.3 ± 7.4

< 0.001*

a (0.01*)

b (< 0.001*)

c (0.01*)

EQ-5D-5L

0.85 ± 0.097

0.79 ± 0.079

0.74 ± 0.129

0.01*

b (< 0.001*)

c (0.01*)

  1. One-Way ANOVA post hoc comparison of Fisher’s Least Significant Difference (LSD). Statistical significance p < 0.05*. Comparison between control group without pain and single body area pain (a), between control group without pain and multisite pain (b), and between single body area pain and multisite pain (c)
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us